Vivos Therapeutics Profit Margin

Vivos Therapeutics (VVOS) currently reports a profit margin of -122.08% as of June 2026. That compares with -99.49% in the prior-year period — down 22.7% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Vivos Therapeutics's profit margin history and peer comparisons.

Vivos Therapeutics's profit margin decreased from -99.49% to -122.08% — a 22.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vivos Therapeutics's profit margin of -122.08% is lower than the Healthcare sector average of 13.89%. That is roughly 978.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Vivos Therapeutics's current -122.08% should be judged against Healthcare norms (sector average: 13.89%) and against VVOS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -122.08%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Vivos Therapeutics, and consider following VVOS for alerts when major investors trade the stock.